Effects of Berberine on the Human Gut Microbiome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJing-yuan Fang, MD, Ph. D
About this trial
Berberine hydrochloride is a conventional component in Chinese medicine. In recent years, anticancer activity of berberine hydrochloride have been explored. The aim of this study is to investigate the effect of berberine hydrochloride on the human gut microbiome.
Eligibility criteria
Qualifiers
Aged 18-75 years;
Had at least one but no more than six histologically confirmed colorectal adenomas (including tubular, tubulovillous, and villous adenomas) removed within 6 months prior to enrollment;
Provide informed consent for this study and are able to comply with the requirements for collecting qualified stool specimens, peripheral blood specimens, and providing relevant lifestyle and medical history information.
Aged 18-75 years;
Disqualifiers
Incomplete resection of adenoma during colonoscopy;
Individuals at high risk for hereditary colorectal cancer;
Regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, calcium, or vitamin D (defined as daily intake of ≥100 mg aspirin and ≥1200 mg calcium for at least 3 months);
History of subtotal gastrectomy, total gastrectomy, or partial enterectomy;
Trial design
Treatments tested in this trial
- Berberine Hydrochloride
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Jing-yuan Fang, MD, Ph. D
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor institution
Shanghai Jiao Tong University School of Medicine
Collaborator
Source ClinicalTrials.gov